3 results
Approved WMOCompleted
To assess the anti-tumor activity of LGX818/MEK162 in combination with third targeted agents after progression on LGX818/MEK162 combination therapy.
Approved WMOCompleted
See protocol page 23This study is designed to assess the usability and functionality of the Reveal LINQ system. Data from the first 30 patients, with 30 days of follow-up, will be used to assess sensing performance and wireless capabilities of the…
Approved WMOCompleted
Primary objectives: 1) Phase Ib: To estimate the MTD or RP2D of INC280 in combination with gefitinib in NSCLC patients who have c-MET dysregulation. 2) Phase II: To estimate overall clinical activity of INC280 in combination with gefitinib in NSCLC…